Suvorexant Cuts 2 Alzheimer’s-Linked Proteins in 38 Adults After 2 Nights
Updated
Updated · Futura · Jul 13
Suvorexant Cuts 2 Alzheimer’s-Linked Proteins in 38 Adults After 2 Nights
2 articles · Updated · Futura · Jul 13
Summary
Two nights of suvorexant lowered amyloid-beta and tau levels in 38 middle-aged adults without cognitive impairment, according to a Washington University study in Annals of Neurology.
The findings add evidence that sleep helps clear brain waste, and researchers say improving sleep could become a route to slowing or preventing Alzheimer’s-related protein buildup.
Brendan Lucey cautioned the effect was modest and short-term, saying it is too early for people worried about Alzheimer’s to start taking the insomnia drug nightly.
The study did not test whether longer use changes disease progression, leaving broader questions about durability, safety and real-world prevention benefits unanswered.
A sleeping pill reduces Alzheimer's toxins in two nights, but can it outperform our brain's natural deep-sleep cleaning?
We're told more sleep prevents dementia, so why does new research show it can sometimes accelerate cognitive decline?
As a new 2026 theory challenges Alzheimer's cause, are drugs that clear brain plaques simply missing the real target?
FDA-Approved Sleep Drug Suvorexant Shows Immediate Impact on Alzheimer’s Proteins in Proof-of-Concept Study
Overview
Recent research has revealed that suvorexant, an FDA-approved insomnia medication, can acutely influence key proteins linked to Alzheimer’s disease, specifically amyloid and tau. In a small proof-of-concept study, suvorexant was shown to affect the brain’s protein dynamics, marking a significant step toward new prevention or treatment strategies for Alzheimer’s. These findings are important because they suggest a new use for an existing, widely available drug with a proven safety record. However, experts emphasize that more research is needed before suvorexant can be recommended for Alzheimer’s prevention.